Trial Profile
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2021
Price :
$35
*
At a glance
- Drugs BNC 105 (Primary) ; Napabucasin (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms MODULATE
- 21 Sep 2021 Primary endpoint has been met. (Objective response per iRECIST), as per Results presented at the 46th European Society for Medical Oncology Congress
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress
- 26 Aug 2021 Status changed from active, no longer recruiting to completed.